Danske Bank A S lessened its stake in Axon Enterprise, Inc (NASDAQ:AXON – Free Report) by 5.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,650 shares of the biotechnology company’s stock after selling 3,060 shares during the period. Danske Bank A S owned 0.07% of Axon Enterprise worth $23,091,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of the stock. State Street Corp boosted its position in Axon Enterprise by 5,700.2% in the 2nd quarter. State Street Corp now owns 213,561,844 shares of the biotechnology company’s stock valued at $119,724,905,000 after buying an additional 209,879,882 shares during the last quarter. Envestnet Asset Management Inc. raised its position in shares of Axon Enterprise by 18,050.2% during the second quarter. Envestnet Asset Management Inc. now owns 13,200,075 shares of the biotechnology company’s stock worth $7,400,094,000 after acquiring an additional 13,127,348 shares during the last quarter. BlackRock Inc. raised its position in shares of Axon Enterprise by 4.3% during the second quarter. BlackRock Inc. now owns 8,334,551 shares of the biotechnology company’s stock worth $4,672,432,000 after acquiring an additional 345,365 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its position in shares of Axon Enterprise by 391,214.9% during the third quarter. Robeco Institutional Asset Management B.V. now owns 6,988,884 shares of the biotechnology company’s stock worth $2,952,943,000 after acquiring an additional 6,987,098 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Axon Enterprise by 5,022.8% during the third quarter. Assenagon Asset Management S.A. now owns 4,266,589 shares of the biotechnology company’s stock valued at $1,802,719,000 after acquiring an additional 4,183,302 shares during the period. Institutional investors own 79.08% of the company’s stock.
Analysts Set New Price Targets
AXON has been the topic of several recent research reports. Citigroup reiterated a “market outperform” rating on shares of Axon Enterprise in a report on Monday, November 2nd. Raymond James Financial set a $675.00 price objective on Axon Enterprise in a report on Thursday, October 15th. Barclays cut their target price on shares of Axon Enterprise from $688.00 to $507.00 and set an “overweight” rating on the stock in a research report on Monday, November 9th. Royal Bank Of Canada reduced their target price on shares of Axon Enterprise from $735.00 to $615.00 and set an “outperform” rating on the stock in a research note on Friday, November 6th. Finally, UBS Group raised their target price on shares of Axon Enterprise from $440.00 to $600.00 and gave the company a “neutral” rating in a research note on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $612.18.
View Our Latest Report on Axon Enterprise
Insider Activity
In other Axon Enterprise news, President Joshua Isner sold 16,775 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $574.43, for a total value of $9,636,063.25. Following the completion of the sale, the president owned 296,974 shares of the company’s stock, valued at approximately $170,590,774.82. This represents a 5.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey C. Kunins sold 9,605 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $626.70, for a total transaction of $6,019,453.50. Following the completion of the sale, the insider directly owned 97,761 shares of the company’s stock, valued at $61,266,818.70. The trade was a 8.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 37,397 shares of company stock valued at $21,234,034. Insiders own 4.20% of the company’s stock.
Axon Enterprise Trading Down 2.9%
NASDAQ AXON opened at $306.44 on Tuesday. Axon Enterprise, Inc has a 12 month low of $291.45 and a 12 month high of $665.07. The stock has a 50-day simple moving average of $413.60 and a 200 day simple moving average of $466.47. The company has a current ratio of 3.00, a quick ratio of 2.60 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $24.95 billion, a PE ratio of 98.22, a P/E/G ratio of 5.84 and a beta of 1.48.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last issued its earnings results on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.17). The company had revenue of $908.55 million for the quarter, compared to the consensus estimate of $934.33 million. Axon Enterprise had a return on equity of 3.87% and a net margin of 7.56%. Axon Enterprise’s quarterly revenue was up 27.8% on a year-over-year basis. During the same quarter last year, the business posted $1.17 EPS. Research analysts forecast that Axon Enterprise, Inc will post 2.10 EPS for the current year.
Axon Enterprise Profile
Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals. The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.
See Also
- Five stocks we like better than Axon Enterprise
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.
